Skip to main content

Research & Treatments

targeted oncology
ResearchTreatments

Rezivertinib Generates Promising CNS Efficacy in NSCLC With an EGFR T790M Mutation

*June 2023* Rezivertinib (BPI-7711) showed promising clinical central nervous system (CNS) efficacy among patients with advanced non–small cell lung cancer (NSCLC) with EGFR T790M mutation and CNS metastases.​​ The study included individual data from 2 different single-arm, phase 1 (NCT03386955) and phase 2b studies (NCT03812809) to assess the CNS response of rezivertinib…
laurabbook@gmail.com
September 29, 2023
Onc Live
ResearchTreatments

Continued Emergence of Targeted Therapies for EGFR-Mutant NSCLC Underscores Importance of Molecular Testing

*July 2023* With osimertinib (Tagrisso) available as a treatment option in both the metastatic and adjuvant settings for patients with EGFR-mutated non–small cell lung cpatients with EGFR-mutated non–small cell lung cancer ancer (NSCLC) and ongoing trials evaluating combination therapies for this patient population, molecular testing to identify these aberrations in patients with…
laurabbook@gmail.com
September 29, 2023
Lung-Map logo
ResearchTreatments

Advocating, Accelerating, and Amplifying Lung Cancer Discovery: Lung-MAP Advocacy Webinar Replay

*July 2023* The Lung-MAP Accrual Enhancement Committee (AEC) hosted this webinar which featured leading experts from the current Lung-MAP clinical trial to discuss recent trial updates, challenges to the traditional clinical trial landscape that Lung-MAP is working to overcome, and opportunities for patient engagement in the process. Importantly, the webinar featured a panel…
laurabbook@gmail.com
September 29, 2023
Medpage Today ASCO Reading Room
ResearchTreatments

Updates in EGFR-Mutated Oligometastatic NSCLC

*June 2023* In Hollywood, the word "mutant" generally has a negative connotation, with movie plot lines that involve rogue mutants, mercenary mutants, or hunted mutants. But in the lung cancer space, harboring an EGFR mutation may confer an advantage. In a study that sought to pinpoint survival outcomes for patients with synchronous oligometastatic…
laurabbook@gmail.com
September 29, 2023
ResearchTreatments

Pembro Plus Chemo Fails to Show Efficacy Benefit in TKI-Resistant, EGFR-Mutated, Metastatic Nonsquamous NSCLC (KEYNOTE-789)

*June 2023* Key Points: KEYNOTE-789 did not show a significant improvement in PFS or OS with the addition of pembrolizumab to chemotherapy in patients with TKI-resistant EGFR-mutated metastatic nonsquamous NSCLC. There remains a need for more effective treatment strategies for patients with EGFR-mutated NSCLC. An analysis from the randomized, phase 3 KEYNOTE-789…
laurabbook@gmail.com
September 29, 2023
EGFR Resister Logo
ResearchTreatments

Research Update: EGFR Resisters + LCRF

*June 2023* EGFR Resisters and LCRF are delighted to update supporters about the research made possible by their partnership! The EGFR Resisters Grant was awarded in 2021 to Yang Tian, PhD, Icahn School of Medicine at Mount Sinai. She joins us along with Hideo Watanabe, MD, PhD, who leads The Watanabe…
laurabbook@gmail.com
September 29, 2023